Adaptive Phage Therapeutics (APT) is advancing therapies that treat multidrug resistant infections. Antimicrobial resistance (AMR) due to bacterial evolution limits the effectiveness and useful lifespan of many therapeutic antibiotics continuing to create a world-wide crisis. APT is addressing this problem by targeting the emergence of future antibiotic-resistant bacteria with bacteriophages (“phages”) that are the most prolific killers of bacteria. Phages are specific to bacteria and overcome challenges caused by antibiotics such as evolvability to new resistant strains, safety to human cells and the range of bacteria affected - typically a single phage targets a single bacterial strain. APT is growing a PhageBankTM to find phages that target resistant bacterial pathogens.
Claim company profile to post jobs directly on this page and this website.